Compare Mesoblast Limited (MESO) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Snap On Incorporated — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Snap On Incorporated trades at $358.97 (market cap $18.56B). The key difference: Snap On Incorporated is far larger — about 10.6× Mesoblast Limited's market cap, and Snap On Incorporated pays a 2.72% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Snap On Incorporated for 36 Days on average.
| MESO | SNA | |
|---|---|---|
Market Cap | $1.75B | $18.56B |
Volume | 239,027 | 401,326 |
Sector | Health | Industrials |
52-Week High | $20.96 | $419.31 |
52-Week Low | $13.19 | $327.33 |
Typical Hold Time | 14 Days | 36 Days |
Enterprise Value | $1.83B | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Snap-On Incorporated (SNA) trades at $359.89, down 2.37% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company maintains robust profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $449 price target, representing 25% upside potential from current levels.
SNA offers attractive fundamentals with expanding gross margins and solid cash flow generation, though technical weakness and premium valuation present near-term headwinds. The stock's investment case hinges on continued execution of RCI initiatives and diagnostic segment growth, balanced against valuation concerns and mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
